MOG and myeloid sarcoma: Future work will examine whether the models developed in this study can be applied to childhood forms of demyelinating disease (in which MOG-Abs are commonly detected [15]), aid classification of heterogeneous cohorts such as antibody-negative NMOSD and atypical MS, and whether the discriminatory metabolites can be utilized as biomarkers for disease activity.